These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28511335)

  • 1. [Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].
    Wu NQ; Li JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):444-446. PubMed ID: 28511335
    [No Abstract]   [Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 inhibitors on the horns of a dilemma: which lipoprotein we should primarily target - low-density lipoprotein or lipoprotein(a)?
    Papazoglou AS; Koliastasis L; Milkas A
    J Cardiovasc Med (Hagerstown); 2022 Sep; 23(9):635-636. PubMed ID: 35994711
    [No Abstract]   [Full Text] [Related]  

  • 3. Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.
    Packard CJ
    Circulation; 2017 Jan; 135(4):363-365. PubMed ID: 28115413
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid-Lowering Therapy With Monoclonal Antibodies to Proprotein Convertase Subtilisin-Kexin Type 9　- Lessons From Recent Clinical Trials.
    Ishii H; Murohara T
    Circ J; 2017 Sep; 81(10):1386-1387. PubMed ID: 28579602
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.
    Cao YX; Li JJ
    Diabetes Care; 2018 Apr; 41(4):e69. PubMed ID: 29559466
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.
    de Carvalho LSF; Campos AM; Sposito AC
    Diabetes Care; 2018 Apr; 41(4):e70-e71. PubMed ID: 29559467
    [No Abstract]   [Full Text] [Related]  

  • 7. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol.
    Wierzbicki AS
    Curr Opin Lipidol; 2007 Apr; 18(2):227-9. PubMed ID: 17353672
    [No Abstract]   [Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value.
    Mark DB; Richman I; Hlatky MA
    JAMA Cardiol; 2017 Oct; 2(10):1066-1068. PubMed ID: 28832860
    [No Abstract]   [Full Text] [Related]  

  • 10. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes "DAMP".
    Silverstein RL
    Circulation; 2021 Jan; 143(1):62-64. PubMed ID: 33378238
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report.
    Kotani K; Sakane N
    J Appl Lab Med; 2020 Sep; 5(5):1124-1126. PubMed ID: 32674159
    [No Abstract]   [Full Text] [Related]  

  • 17. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 genetic screening using the vervet (Chlorocebus aethiops) model.
    Ngqaneka T; Obikeze K; Magwebu ZE; Chauke CG
    J Med Primatol; 2023 Feb; 52(1):45-52. PubMed ID: 36222294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.